The global psoriatic arthritis (PsA) treatment market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As such, the sector is anticipated to progress at a CAGR of 7.8%.
The need for psoriatic arthritis (PsA) treatment arises as a result of psoriasis affecting a significant number of people globally. It is claimed that about 125 million people worldwide suffer from the disease. As the number of people affected by the disorder continues to climb, the need for related treatment increases too.
Psoriasis majorly affects people in the 50-60 age range, being the pinnacle age where the symptoms first start showing. As the population of the world is aging rapidly, more people with psoriatic arthritis are populating hospitals. As such, the patient pool for the treatment is getting wider.
It's not just the geriatric population that comprises the patient pool, 20 to 30 is another prominent age when the symptoms of psoriasis start showing. Thus, the psoriatic arthritis (PsA) treatment market is advancing through multiple avenues.
Psoriatic arthritis can lead to conditions that drive people to seek treatment fast. Conditions like morning stiffness, nail pitting, flaky scalp, and more affect patients majorly. Thus, a rising number of people are turning to the treatment.
There are some downsides to the industry, however. The high cost of certain treatments deters patients from taking its help. The side effects of medication for psoriatic arthritis, which may include infection, lung inflammation, hair loss, and more, also prove to be a negative point.
Online consulting and treatment options also help the sector move into the modern digital world. As such, the easy availability of medicine and treatment options is leading to demand being established at a faster rate.
| Attributes | Description |
|---|---|
| Established Value for 2024 | USD 11,973.7 million |
| Projected Value for 2034 | USD 25,375.6 million |
| Value-based CAGR from 2024 to 2034 | 7.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Variety of Treatment Options Make the Psoriatic Arthritis (PsA) Treatment Market’s Case Easier
The wide variety of treatment options available boosts the industry. These treatment options range from over-the-counter drugs to extensive surgeries. Some of the treatment options available include biologics, steroid injections, and joint replacement surgeries. Regulatory bodies like the Food and Drug Administration (FDA) approving new treatments at a rapid rate also help the ascent of the sector. Some medications that have received approval from the FDA in recent times include Guselkumab and Risankizumab-rzaa.
Constant Clinical Trials Keep the Industry from Becoming Stagnant
As new drugs get approved at a rapid rate, pharma companies and health institutions are looking to refine treatment further. Trails for starting new types of medication are common. Pharma sector players are investing significant amounts of money in these trials. Government grants are also helping in this venture. Some of the promising drugs under trial currently are Bimekizumab and Netakimab. Thus, the industry’s prospects remain fresh.
Treatment Options Going Online Helps Sales to Flourish
Digital pharmacies and telehealth are set to play a significant part in the industry’s development. With the help of online pharmacies, suppliers are making the medications available at a moment’s notice, making patients more inclined towards the treatment.
The psoriatic arthritis (PsA) treatment market advanced at a rate of 7.4% for the period between 2019 to 2023. While the 2019 value was tipped to be USD 7,816.3 million, the 2023 value jumped to USD 11,153.9 million.
The pandemic served to divert attention away from disorders other than Covid-19. Clinical trials too were concentrated majorly on finding vaccines and treatments for the disease. As such, the treatment’s growth rate was negatively affected.
However, the industry grew in other ways in the historical period. The rise of telehealth, digital pharmacies, and online consultations gave a new look to the market.
The sector is set to advance at a higher rate in the forecast period as compared to the historical period. Much of the success of the treatment going forward is predicated on the role of regulatory bodies. As more treatments get approved, the industry is set to flourish. If the treatments get approved as quickly as they have been historically, the industry’s progress is set to be swift.
Alternative treatments of psoriatic arthritis are also set to gain more prominence in the coming decade. For example, light therapy and acupuncture are treatments that are becoming more popular.
Principal Consultant
Biologics are the top type of drugs administered for the disease. Medications for the disorder are overwhelmingly taken through the injectable mode.
Biologics are penned in to take up 57.2% of the market share in 2024.
Disease-modifying antirheumatic drugs (DMARDs) have been the go-to treatment options prescribed by doctors. DMARDs like methotrexate have been relied upon by doctors historically. However, biological versions of DMARDs are coming to the fore.
Biologics have proven themselves to be effective in combatting inflammation, swelling, and other conditions caused by psoriatic arthritis. The treatment type is also reported to cause fewer side effects as compared to standard drugs.
The adoption of biologics is also helped by regulatory bodies approving their use at a fast rate. The approval of biologics like adalimumab (Humira) and ixekizumab (Taltz) helps the segment emerge on top in the drug type category.
| Attributes | Details |
|---|---|
| Top Drug Type | Biologics |
| Industry Share (2024) | 57.2% |
For 2024, injectable drugs are predicted to remain at the top, with a share of 84.9%.
Injectable drugs have established themselves as the preferred treatment option by both doctors and patients. Injectable versions of the drugs are generally reputed to act faster in treatment as compared to oral drugs. Thus, their dominance continues in the route of administration segment.
| Attributes | Details |
|---|---|
| Top Route of Administration | Injectable |
| Industry Share (2024) | 84.9% |
The drive to make drugs and medications available in rural areas broadens the market’s scope in the Asia Pacific. The aging population in North America necessitates the recourse of treatment in the region.
| Countries | CAGR (2024 to 2034) |
|---|---|
| Japan | 7% |
| China | 8.4% |
| United States | 7.5% |
| South Africa | 6.6% |
| United Kingdom | 7.6% |
| Canada | 7% |
| Italy | 6.8% |
| Germany | 7.8% |
| France | 7.3% |
| Spain | 6.5% |
| India | 8.9% |
| Australia | 7.9% |
The United States is set to witness the industry progress at a CAGR of 7.5% over the forecast period. The population of the United States is getting older at a concerning rate. It is estimated that by 2040, one in five Americans will be over the age of 65. Thus, the conditions are right for the psoriatic arthritis (PsA) treatment market to flourish in the country.
The sector is set to expand at a CAGR of 8.9% in India, making the country lucrative for players. National health schemes by the government target the raising of awareness relating to psoriasis aid the sector’s growth in India. Foreign pharma companies like Eli Lilly are making efforts to introduce new drugs and modernize the treatment procedure in India.
The United Kingdom is set to see market growth happen at a CAGR of 7.6% over the coming decade.
The market in the United Kingdom is developing as a result of new drugs being developed and approved at a satisfactory pace. For example, in 2022, Rinvoq (upadacitinib), manufactured by AbbVie received clearance from the United Kingdom National Institute for Health and Care Excellence (NICE) for the treatment of adult patients with psoriatic arthritis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The development of new drugs remains a priority for players. In addition, collaborative strategies are also part of the vision. Partnerships with public bodies are sought to raise awareness about the disease.
The need for developing novel drug options is evident when looking at an industry giant like Pfizer Inc. The company also partners with other healthcare sector players for the development of new drugs. Johnson and Johnson also concentrate on new drug development, investing significant amounts into trials.
Recent Developments in the Psoriatic Arthritis (PsA) Treatment Market
Key companies in the industry include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC.
Based on the drug type, the psoriatic arthritis (PsA) treatment market can be segmented into the following segments: non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs, and biologics. Disease-modifying anti-rheumatic drugs can be further separated into corticosteroids, antimalarial, methotrexate, and others. On the other hand, biologics can be bifurcated into TNF inhibitors and interleukin inhibitors.
Based on the route of administration, the psoriatic arthritis (PsA) treatment market can be bifurcated into the following segments: injectable and oral.
Based on the distribution channel, the psoriatic arthritis (psa) treatment market can be segmented into the following segments: hospital pharmacies, retail pharmacies, and mail-order pharmacies.
The sector has been analyzed with the following regions covered: North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.
The size of the psoriatic arthritis (PsA) treatment sector is estimated to be USD 11,973.7 million in 2024.
The industry is expected to increase at a CAGR of 7.8% over the forecast period.
Sales are expected to register a CAGR of 7.5% in the United States over the period from 2024 to 2034.
The psoriatic arthritis (PsA) treatment sector is forecasted to reach a size of USD 25,375.6 million by 2034.
Pfizer Inc., Johnson & Johnson, AbbVie Inc., and Amgen Inc. are some of the prominent companies in the industry.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Product Type 6.2. Route of Administration 6.3. Distribution Channel 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type 7.1. Non-Steroidal Anti-Inflammatory Drugs 7.2. Disease Modifying Anti-Rheumatic Drugs 7.2.1. Corticosteroids 7.2.2. Antimalarial 7.2.3. Methotrexate 7.2.4. Others 7.3. Biologics 7.3.1. TNF Inhibitors 7.3.2. Interleukin Inhibitors 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 8.1. Injectable 8.2. Oral 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Mail Order Pharmacies 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. South Asia 10.5. East Asia 10.6. Eastern Europe 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Product Type, Route of Administration, and Distribution Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Pfizer Inc. 20.2. Johnson & Johnson 20.3. AbbVie Inc. 20.4. Amgen Inc. 20.5. Bristol-Myers Squibb Company 20.6. UCB S.A. 20.7. Eli Lilly & Co 20.8. Novartis AG 20.9. Celgene Corporation 20.10. AstraZeneca PLC
Explore Healthcare Insights
View Reports
Psoriatic Arthritis (PsA) Treatment Market
